NXL
Nexalin Technology, Inc.
Key Financials
Revenue
$301647
↑ 78.8%
Net Income
$-8222181
↓ 8.1%
Operating Income
$-8390881
↓ 8.2%
EPS (Diluted)
$-0.50
↑ 39.8%
Total Liabilities
$887333.00
↑ 62.3%
Gross Profit
$240274
↑ 81.8%
Shareholders' Equity
$3.7M
↑ 2.0%
Total Assets
$4.6M
↑ 9.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-K | 3/25/2026 | View on SEC |
| 8-K | 2/25/2026 | View on SEC |
| 8-K | 1/23/2026 | View on SEC |
| 4 | 12/23/2025 | View on SEC |
| 4 | 12/23/2025 | View on SEC |
| 4 | 12/23/2025 | View on SEC |
| 4 | 12/23/2025 | View on SEC |
| 4 | 12/23/2025 | View on SEC |
| 4 | 12/23/2025 | View on SEC |
| 8-K | 12/5/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | NXL |
| Company Name | Nexalin Technology, Inc. |
| CIK | 1527352 |
| Sector | Electromedical & Electrotherapeutic Apparatus |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 3845 |
| SIC Description | Electromedical & Electrotherapeutic Apparatus |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (832) 260-0222 |